Oral Anticoagulant Comparisons    body {font-family: 'Open Sans', sans-serif; padding-left: 10px;}

### Oral Anticoagulant Comparisons

table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Drug | Warfarin | Dabidatran | Rivaroxaban | Apixaban |
| --- | --- | --- | --- | --- |
| Target | IIa, VIIa, IXa, Xa | IIa | Xa | Xa |
| Peak Effect | 4-5 days | 1.5-3 hours | 2-4 hours | 1-3 hours |
| Half-life | 40 hours | 12-17 hours | 5-9 hours | 9-14 hours |
| Renal elim. | None | 80% | 33% | 25% |
| Dialyzable | No | Yes | No | No |
| Interactions | Many | P-gp | 3A4, P-gp | 3A4, P-gp |
| Monitoring | Yes | No | No | No |
| Antidote | Vitamin K | idarucizumab | FDA Pending | FDA Pending |
| Labs | INR | TT, ECT | Anti-Xa assay | Anti-Xa assay |

P-gh = p glycoprotein  
Cove CL, Hvlek EM. T Am Heart Assoc  
3A4 = cytochrome p450 3A4  
  
**Oral Anticoagulant Labs**

table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Test | Dabigatran | Rivaroxaban | Apixaban |
| --- | --- | --- | --- |
| aPTT | ↑ ↑ no correlation | ↑ (no correlation) | ↑ (no correlation) |
| PT | ↑ no correlation | ↑ ↑ (no correlation) | ↑ (no correlation) |
| INR | ↑ no correlation | ↑ (no correlation) | ↑ (no correlation) |
| TT | ↑ ↑ ↑ reliable | No effect | No effect |
| ECT | ↑ reliable | No effect | No effect |
| Anti-Xa | No effect | ↑ ↑ most reliable | ↑ ↑ most reliable |

Hillarp AJ, Throm Haenost, 2011;9 133-139 TT (Thromb)  
Funk DM, Hematology 2012l 460-465. ECT (Ecarin Clotting Time)  
Frost et al, Br Clin Pharmacol 2012; 75: 476  
Garcia D et al. J Thromb 2013;11:245-52